Characteristics | n (%) |
---|---|
Sex | |
 Male | 25 (83.3) |
 Female | 5 (16.7) |
T stage of initial diagnosis on MRI | |
 T1 |  |
 T2 | 12 (40.0) |
 T3 | 13 (43.3) |
 T4 | 5 (16.7) |
N stage of initial diagnosis on MRI | |
 N0 | 3 (10.0) |
 N1 | 14 (46.7) |
 N2 | 8 (26.7) |
 N3 | 5 (16.7) |
RLN metastasis detected in the initial diagnosis on MRI | |
 Yes | 19 (63.3) |
 No | 11 (36.7) |
Recurrent disease site detected via MRI | |
 Right lateral RLN | 13 (43.3) |
 Left lateral RLN | 16 (53.3) |
 Medial RLN | 1 (3.3) |
Previous chemo/radiotherapy regime | |
 Neoadjuvant chemotherapy plus radiotherapy | 7 (23.3) |
 Radiotherapy plus adjuvant chemotherapy | 6 (20.0) |
 Concomitant chemo-radiotherapy | 16 (53.3) |
 Radiotherapy only | 1 (3.3) |
Previous chemotherapy agent | |
 Cisplatin only | 16 (53.3) |
 5-flurouracil + cisplatin | 8 (26.7) |
 Paclitaxel + carboplatin | 5 (16.7) |
Previous radiotherapy | |
 Two-dimensional radiotherapy | 18 (60.0) |
 Three-dimensional conformal radiotherapy | 6 (20.0) |
 Intensity-modulated radiotherapy | 6 (20.0) |
Duration between chemo-radiotherapy and detection of suspicious recurrent RLN | |
 6–12 months | 6 (20.0) |
 1–3 years | 13 (43.3) |
 4–5 years | 5 (16.7) |
 5–10 years | 5 (16.7) |
 > 10 years | 1 (3.3) |